Get Social With Us

The Other CAR-T Race: Manufacturing

The biosphere is still buzzing about the FDA’s approval of Kymriah – Novartis’ CAR-T treatment for acute lymphoblastic leukemia that, in many ways, marks the true beginning of the cell and gene therapy era. Approvals of other CAR-Ts are expected soon. But behind the scenes, there’s another race going on:...

Read More

Cheaper Vaccines! Maybe?

I came away from this year’s World Vaccine Congress impressed by two potentially revolutionary technologies that could radically change the cost of vaccines. The first technology, from LimmaTech Biologics AG, is a manufacturing process for producing conjugate vaccines that eliminates the conjugation chemistry steps and further downstream purification by combining the...

Read More

You’re a Good Man Charlie B

We can all heave a sigh of relief. With his recent announcement that he will extend Gov. Deval Patrick’s 10-year, $1 billion life sciences development package – by five years and $500 million – Massachusetts Governor Charlie Baker has finally signaled, unequivocally, that he recognizes the importance of biotechnology and...

Read More

The Value of Flexible Technologies

If you had any doubt that single-use technologies are becoming broadly accepted for commercial biopharmaceutical manufacturing applications, the recent BPI-West conference should put them to rest. The infrastructure and systems are being established at many large manufacturers to enable them to control single-use supply chains for both clinical and commercial...

Read More